LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Cumberland Pharmaceuticals Inc

Geschlossen

2.54 -4.51

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.49

Max

2.61

Schlüsselkennzahlen

By Trading Economics

Einkommen

3.2M

1.2M

Verkäufe

1.3M

12M

EPS

0.082

Gewinnspanne

10.656

Angestellte

91

EBITDA

1.2M

1.3M

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-15M

59M

Vorheriger Eröffnungskurs

7.05

Vorheriger Schlusskurs

2.54

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Cumberland Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

27. Juni 2025, 20:51 UTC

Ergebnisse

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27. Juni 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27. Juni 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27. Juni 2025, 20:48 UTC

Market Talk

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27. Juni 2025, 20:46 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27. Juni 2025, 20:46 UTC

Market Talk

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27. Juni 2025, 19:31 UTC

Market Talk

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27. Juni 2025, 19:19 UTC

Market Talk

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27. Juni 2025, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27. Juni 2025, 18:57 UTC

Akquisitionen, Fusionen, Übernahmen

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27. Juni 2025, 18:57 UTC

Akquisitionen, Fusionen, Übernahmen

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27. Juni 2025, 18:57 UTC

Akquisitionen, Fusionen, Übernahmen

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27. Juni 2025, 18:57 UTC

Akquisitionen, Fusionen, Übernahmen

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27. Juni 2025, 18:57 UTC

Akquisitionen, Fusionen, Übernahmen

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27. Juni 2025, 18:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. Juni 2025, 18:42 UTC

Market Talk

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27. Juni 2025, 18:39 UTC

Market Talk
Ergebnisse

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27. Juni 2025, 18:29 UTC

Market Talk

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27. Juni 2025, 18:18 UTC

Market Talk

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27. Juni 2025, 18:16 UTC

Market Talk

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27. Juni 2025, 17:16 UTC

Market Talk

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27. Juni 2025, 17:08 UTC

Ergebnisse

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27. Juni 2025, 16:52 UTC

Akquisitionen, Fusionen, Übernahmen

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27. Juni 2025, 16:22 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27. Juni 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

27. Juni 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27. Juni 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

27. Juni 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

27. Juni 2025, 15:59 UTC

Market Talk

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27. Juni 2025, 15:56 UTC

Market Talk

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Peer-Vergleich

Kursveränderung

Cumberland Pharmaceuticals Inc Prognose

Technischer Score

By Trading Central

4.325 / 4.845Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Cumberland Pharmaceuticals Inc

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.